FY2025 EPS Forecast for Vera Therapeutics Reduced by Analyst

Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) - Equities researchers at HC Wainwright lowered their FY2025 earnings estimates for shares of Vera Therapeutics in a report issued on Monday, June 2nd. HC Wainwright analyst A. He now anticipates that the company will post earnings per share of ($3.44) for the year, down from their previous estimate of ($3.42). HC Wainwright has a "Buy" rating and a $85.00 price target on the stock. The consensus estimate for Vera Therapeutics' current full-year earnings is ($2.89) per share. HC Wainwright also issued estimates for Vera Therapeutics' Q4 2025 earnings at ($0.86) EPS, Q1 2026 earnings at ($0.81) EPS, Q2 2026 earnings at ($0.79) EPS, Q3 2026 earnings at ($0.84) EPS, Q4 2026 earnings at ($0.20) EPS, FY2026 earnings at ($2.64) EPS, FY2027 earnings at $1.03 EPS, FY2028 earnings at $3.86 EPS and FY2029 earnings at $6.06 EPS.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.06). During the same quarter in the previous year, the business posted ($0.56) EPS.

Other analysts also recently issued reports about the company. Wedbush lowered their price objective on Vera Therapeutics from $34.00 to $26.00 and set a "neutral" rating for the company in a research note on Wednesday, May 7th. Guggenheim increased their price target on shares of Vera Therapeutics from $59.00 to $61.00 and gave the company a "buy" rating in a research report on Thursday, February 27th. Cantor Fitzgerald decreased their target price on Vera Therapeutics from $107.00 to $100.00 and set an "overweight" rating for the company in a research report on Wednesday, May 7th. Scotiabank boosted their price target on shares of Vera Therapeutics from $55.00 to $65.00 and gave the company a "sector outperform" rating in a research report on Monday. Finally, JPMorgan Chase & Co. dropped their price objective on Vera Therapeutics from $77.00 to $71.00 and set an "overweight" rating on the stock in a report on Tuesday, March 4th. One analyst has rated the stock with a hold rating, seven have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $65.00.

Vera Therapeutics Stock Down 4.3%

VERA stock traded down $1.37 during mid-day trading on Wednesday, reaching $30.63. 3,478,292 shares of the company traded hands, compared to its average volume of 878,802. The company has a quick ratio of 13.76, a current ratio of 13.76 and a debt-to-equity ratio of 0.17. The firm's 50 day moving average price is $22.26 and its 200 day moving average price is $31.86. The stock has a market cap of $1.95 billion, a price-to-earnings ratio of -11.74 and a beta of 1.13. Vera Therapeutics has a fifty-two week low of $18.53 and a fifty-two week high of $51.61.

Hedge Funds Weigh In On Vera Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Barclays PLC lifted its holdings in shares of Vera Therapeutics by 94.1% during the 3rd quarter. Barclays PLC now owns 85,395 shares of the company's stock worth $3,774,000 after acquiring an additional 41,394 shares during the last quarter. KBC Group NV raised its position in Vera Therapeutics by 127.2% during the fourth quarter. KBC Group NV now owns 2,477 shares of the company's stock valued at $105,000 after purchasing an additional 1,387 shares in the last quarter. Jennison Associates LLC raised its position in Vera Therapeutics by 82.0% during the fourth quarter. Jennison Associates LLC now owns 813,861 shares of the company's stock valued at $34,418,000 after purchasing an additional 366,763 shares in the last quarter. Legato Capital Management LLC boosted its holdings in shares of Vera Therapeutics by 56.0% in the 4th quarter. Legato Capital Management LLC now owns 13,454 shares of the company's stock worth $569,000 after purchasing an additional 4,831 shares in the last quarter. Finally, Rhumbline Advisers boosted its holdings in shares of Vera Therapeutics by 12.5% in the 4th quarter. Rhumbline Advisers now owns 58,589 shares of the company's stock worth $2,478,000 after purchasing an additional 6,515 shares in the last quarter. Hedge funds and other institutional investors own 99.21% of the company's stock.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.